Leslie's latest interview ...., page-20

Based on LC past performances, like when she kept on pounding about 'beautiful data' for Her-Vaxx, she was proven correct when the IDMC recommends that the trial be wrapped up as soon as possible after their observation that Hervaxx is so good that it is unethical to continue the trial and depriving other patients from access to it. So I guess this time round, she will be proven right again. Especially given that in a previous interview, she only stated 'anecdotal' observation being that the patients were doing very well. Now she actually refer to actually saying that they are seeing the CF33 working as expected. Which means she must have seen the preliminary data and am very happy with it.

So all in all, I am expecting confirmation of Checkvacc working as it should with no toxicity issue. Hopefully with that, IMU can then fast track the rest of the patients instead of having to dose one at a time. That would also bode well for the upcoming Vaxinia trial. For whatever works for Checkvacc, it would most likely work for Vaxinia as they are of the same platform. Just like both the PD1vaxx and Hervaxx working as expected with no toxicity or tolerability issue being from the same B cell platform.

At end of day, patience is all we need while the patients continue to do well. And the longer the patients stay well, beyond what treatment is available out there, IMU share price will take care of itself.